SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?

To: LLCF who wrote (5988)3/21/2002 4:00:33 PM
From: Biomaven  Read Replies (3) | Respond to of 52153
 
DAK,

at best it may be used WITH chemo

My belief is that it remains very much an open question whether the right anti-angiogenesis drug(s) might eventually control cancer without chemo.

So I'd say your "at best" is too harsh.

All this is of course a very different issue than whether ENMD is a good investment or not. I haven't owned ENMD for a while, but I do keep an eye on them.

Note that it has now unexpectedly been discovered that Herceptin has some anti-angiogenic properties:

Message 17224658

Peter



To: LLCF who wrote (5988)3/21/2002 4:47:07 PM
From: JHP  Read Replies (1) | Respond to of 52153
 
<<... it turns out that at best it may be used WITH chemo [a very unpleasent and some think barbaric, albeit the best right now] for incremental gains in the fight against cancer. Maybe I'm wrong, that was my impression when Folkmman first presented several years ago and the stock soared. >>
what are you talking about?
did you read this list?
these are the trials that are going on!
entremed.com


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News